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Abstract
The enzyme glucocerebrosidase (GBA) hydrolyses glucosylceramide (GlcCer) in lyso-
somes. Markedly reduced GBA activity is associated with severe manifestations of Gaucher
disease including neurological involvement. Mutations in theGBA gene have recently also
been identified as major genetic risk factor for Parkinsonism. Disturbed metabolism of
GlcCer may therefore play a role in neuropathology. Besides lysosomal GBA, cells also
contain a non-lysosomal glucosylceramidase (GBA2). Given that the two β-glucosidases
share substrates, we speculated that over-activity of GBA2 during severe GBA impairment
might influence neuropathology. This hypothesis was studied in Niemann-Pick type C
(Npc1-/-) mice showing secondary deficiency in GBA in various tissues. Here we report that
GBA2 activity is indeed increased in the brain of Npc1-/- mice. We found that GBA2 is partic-
ularly abundant in Purkinje cells (PCs), one of the most affected neuronal populations in
NPC disease. Inhibiting GBA2 in Npc1-/- mice with a brain-permeable low nanomolar inhibi-
tor significantly improved motor coordination and extended lifespan in the absence of cor-
rection in cholesterol and ganglioside abnormalities. This trend was recapitulated, although
not to full extent, by introducing a genetic loss of GBA2 in Npc1-/- mice. Our findings point to
GBA2 activity as therapeutic target in NPC.
Introduction
Glucocerebrosidase (GBA) is a membrane-associated enzyme that hydrolyses the β-glucosyl
linkage of glucosylceramide (GlcCer) in lysosomes [1]. Inherited deficiency of GBA due to
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mutations in the GBA gene causes Gaucher disease (GD). This lysosomal storage disorder is
remarkably heterogeneous in onset, progression and nature of symptoms. In severely affected
GD patients with marked reduction in GBA activity neurological symptoms develop. Of inter-
est, mutations in the GBA gene have recently been associated with development of Parkinson
disease (PD) and other Lewy bodies disorders [2]. Mutations in the SCARB2 gene encoding the
membrane protein LIMP2, which mediates the transport of GBA to lysosomes, have also been
reported to constitute a risk factor for PD [3].
Cells do not rely only on GBA to degrade GlcCer. Another glucosylceramidase, the non-
lysosomal GBA2, can also hydrolyze GlcCer to ceramide and glucose in the cytosol [4]. GBA2
is a non-integral membrane-associated protein located at the endoplasmic reticulum and
Golgi [5,6]. Several studies have pointed towards the existence of a compensatory mechanism
between GBA and GBA2 [7–9]. For example, increased GBA2 activity has been recently
reported in brain of Gaucher mice and in leukocytes of Gaucher patients [7]. We earlier spec-
ulated that GBA2 might be involved in GD etiology [9,10]. Very recently, Mistry and col-
leagues demonstrated that Gba2 gene deletion rescues the visceral, hematologic, and skeletal
phenotype in a non-neuronopathic GD mouse model with impaired GBA activity in the white
blood cell lineage [8]. Unfortunately, this animal model is not suitable to study the impact of
GBA2 on neurological manifestations. An alternative approach to study this is offered by Nie-
mann-Pick type C (NPC) disease. It is well documented that in tissues and cultured fibroblasts
of NPC patients, GBA activity is secondarily reduced [11–13]. NPC is a neurodegenerative
lysosomal storage disease caused by loss-of-function mutations in either the Npc1 or Npc2
genes, encoding proteins essential for the export of cholesterol from lysosomes [14]. NPC
patients develop ataxic gait, motor dysfunction and seizures [15]. Next to accumulation of
cholesterol, glycosphingolipids (GSLs), particularly gangliosides, accumulate in the brain of
NPC patients [15]. A mouse model for NPC, Npc1-/- mice, is available that offers a phenocopy
of the disease in man, including the characteristic neurological manifestations such as a strik-
ing defect in motor coordination [16]. We therefore examined whether compensation
between GBA and GBA2 occurs in Npc1-/- mice, and if so, whether GBA2 activity mediates
neuropathology in the animals and is amenable to pharmacological correction with specific
inhibitors. Here we report the outcome of our investigation pointing to GBA2 activity as a
potential therapeutic target in NPC.
Material and Methods
Animal studies
Npc1-/- mice, along with wild-type littermates (Npc1+/+), were generated by crossing Npc1+/-
males and females in-house. The heterozygous BALB/c Nctr-Npc1m1N/J mice (stock number
003092) were obtained from The Jackson Laboratory (Bar Harbor, USA). Mouse pups were
genotyped according to published protocols [16]. Mice (± 3 weeks old) received the rodent
AM-II diet (Arie Blok Diervoeders, Woerden, The Netherlands). For the treatment groups,
n = 6 per group unless stated differently, the diet was supplemented with 6 or 30 mg MZ-21 or
MZ-31 per kilogram AM-II diet to obtain the doses of 1 and 5 mg per kg body weight per day,
respectively.
The Gba2-/- mice (C57Bl/6-129S6/SvEv mixed background) were generated as previously
described [17]. Npc1-/-/Gba2-/- mice were generated by crossing single heterozygous Npc1+/-
and single knockout Gba2-/- mice to produce compound heterozygotes. These mice were
crossed to generate double-knockout mice and other combinations. All the mice generated
have 50% 129S6/SvEv-C57Bl/6 and 50% BALB/c background. Body weight, physical activity
and motor coordination of the mice were monitored (n = 5–6 per group).
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Objective criterion for final euthanasia of Npc1-/- mice, along with WT controls, was weight
loss greater than 30% of peak weight accompanied by hunched posture and reduced activity.
We also checked that at this stage the animals were no longer able to remain upright due to
trembling/shaking. Mice body weight was recorded on a Tuesday-Friday schedule. Once a
week a movie of 1 min was made to record the clinical symptoms. There were no unexpected
deaths of animals used in the study. When the mice presented reduced activity hydration gel
packs and wet food were placed in the cage to facilitate access to fluids and food. Animals were
anesthetized and sacrificed by cervical dislocation (see next section for details).
The mice were housed at the Institute Animal Core Facility in a temperature- and humid-
ity-controlled room with a 12-h light/dark cycle and given free access to food and water ad libi-
tum. All animal protocols were approved by the Institutional Animal Welfare Committee of
the Academic Medical Centre Amsterdam in the Netherlands.
Tissue processing and immunohistochemistry
Animals were first anesthetized with a dose of Hypnorm (0.315 mg/mL fenyl citrate and 10
mg/mL fluanisone) and Dormicum (5 mg/mL midazolam) according to their weight. The
given dose was 80μL/10g body weight. Blood was collected by a heart puncture followed by cer-
vical dislocation. Brains were dissected, rinsed with phosphate-buffered saline (PBS) and
divided by median section. The left half was fixed in phosphate-buffered formalin and further
used for histology. The right half of non-perfused brain was snap frozen in liquid N2 and stored
at -80°C for biochemistry. Later, homogenates from the frozen material were made in 25 mM
potassium phosphate buffer, pH 6.5, supplemented with 0.1% (v/v) Triton X-100 and protease
inhibitors.
Formalin-fixed, paraffin-embedded tissue was sectioned at 4-μm thickness, dried overnight
at 37°C, deparaffinized in xylene and rehydrated in graded alcohol. Endogenous peroxidase
activity was blocked by incubation for 10 min in methanol containing 0.3% H2O2. Sections
were rehydrated and slides were heated in 0.04 M citrate, 0.12 M phosphate, pH 5.8, for 10 min
at 121°C. After washing, the sections were incubated with primary antibody being either poly-
clonal rabbit IgG anti-mouse GBA2 (#25, 1:500; produced by Eurogentec [Maastricht, The
Netherlands] with the peptides CGSPEDSGPQDEPSY and GRYYNYDSSSHPQSR), polyclonal
rabbit IgG anti-calbindin D-28K (PC253L, 1:1,000; Calbiochem, San Diego, CA, USA), poly-
clonal rabbit IgG anti-GBA (C-terminal, G4171, 1:1,000, Sigma-Aldrich, St Louis, MO, USA),
polyclonal rabbit IgG anti-GFAP (Z0334, 1:2,000; Dako, Glostrup, Denmark), or monoclonal
mouse IgG1 anti-neurofilament (2F11, 1:250; Thermo Fisher Scientific, Rockford, IL, USA) in
Antibody Diluent (ImmunoLogic, Klinipath, Duiven, The Netherlands) for 16 hours at 4°C,
washed, and incubated with secondary antibody being either poly-HRP goat anti-rabbit IgG
(BrightVision, ImmunoLogic), or HRP-conjugated rabbit IgG anti-rat IgG (P0450, 1:3,000;
DAKO) followed by poly-HRP goat anti-rabbit IgG, or HRP-conjugated goat anti-mouse IgG1
(1070–05; SouthernBiotech, Birmingham, AL, USA). HRP activity was detected using 3,3’-dia-
minobenzidine as substrate. Sections were counter-stained with hematoxylin and mounted
with pertex.
In addition, after blocking endogenous peroxidase activity and epitope retrieval as indicated
above, sections were subsequently incubated with 5% (v/v) normal goat serum, rabbit anti-
GBA, and intestinal alkaline phosphatase-conjugated goat anti-rabbit IgG (BrightVision,
ImmunoLogic). Intestinal AP activity was detected using VectorBlue substrate (SK-5300; Vec-
tor Laboratories, Burlingame, CA, USA) in presence of 0.2 mM levamisole to inhibit endoge-
nous non-intestinal alkaline phosphatase activity. Next, epitope retrieval (10 min, 121°C) in
citrate buffer (pH 5.8) was applied to remove all antibodies [18]. Subsequently, sections were
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incubated with normal goat serum, rabbit anti-GBA2, and HRP-conjugated goat anti-rabbit
IgG. HRP activity was detected using ImmPACT AMEC Red substrate (SK-4285; Vector Labo-
ratories). Sections were counterstained with methyl green and mounted with VectaMount
(Vector Laboratories). Analysis was performed using brightfield microscopy (Leica DM5000B)
with an HC PLAN APO 20x/0.70 objective. Multispectral data sets were acquired using a
Nuance imaging system (Perkin Elmer, Hopkinton, MA, USA) from 420 to 720 nm at intervals
of 10 nm. Spectral libraries for each chromogen were obtained from single-stained sections and
were used to unmix the triple staining patterns. Nuance 3.0.2 software was used to construct
composite images applying color universal design. Images were color inverted using Adobe
Photoshop to enhance visibility for color-blind individuals.
In vivo labeling of GBA2 in rat brain
Wistar rats (300 g) (Charles River Laboratories, Wilmington, MA, USA) were implanted with
intracerebroventricular (ICV) cannulas using the coordinates: AP -0.9, L +2.0 and V -3.4. After
a recovery period conduritol-β-epoxide (1 μM) was infused at a rate of 1 μL per minute for 10
min. After one hour, ABP 1 (10 nM) [19] was infused at a rate of 1 μL per minute for 10 min.
After 4 h the animals were sacrificed and the brains were frozen. Thirty-μm-thick cryostat sec-
tions were prepared and extensively washed. After overnight incubation with rabbit anti-cal-
bindin D-28K antibody, the secondary Alexa-488-conjugated donkey anti-rabbit IgG antibody
(R37116, Invitrogen, Carlsbad, CA, USA) was added and incubated for 1 h at RT. The sections
were mounted with Vectashield (Vector Laboratories, Burlingame, CA, USA) containing DAPI
and fluorescence was imaged using confocal laser scanning microscopy (Leica TCS SP5, Leica
Microsystems, Wetzlar, Germany).
Enzyme activity assays
All 4-methylumbelliferyl (4-MU) substrates used were obtained from Sigma (Sigma-Aldrich,
Germany). GBA activity was assayed as previously described [20]. GBA2 activity was assayed
in McIlvaine buffer, pH 5.8, with 0.1% (w/v) BSA, after pre-incubation with 100 nMMDW933
[20] for 30 min at 37°C. Β-hexosaminidase activity was measured with 1.97 mM 4-MU-N-
acety-β-D-glucosaminide in 150 mM citrate-Na2HPO4 (pH 4.0) buffer. Β-glucuronidase activ-
ity was measured with 2 mM 4-MU-β-D-glucuronide in 100 mM sodium acetate (pH 4.8)
buffer.
Gel electrophoresis and fluorescence scanning
Electrophoresis in sodium dodecylsulfate (SDS) containing 7.5% polyacrylamide gels was per-
formed as earlier described [19].
Western Blot
Equal amounts of protein (50 μg) were subjected to electrophoresis on 7.5% SDS-polyacryl-
amide gels and then transferred to nitrocellulose membranes (Whatman, Dassel, Germany)
using an electroblotting apparatus (Bio-Rad Laboratories, Hercules, CA, USA). The blots were
blocked in 5% (w/v) nonfat dried milk in TBST buffer (10 mM Tris-HCl [pH 8.0], 150 mM
NaCl, 0.05% [v/v] Tween-20) and probed with anti-GBA2 (1:1,000), anti-GBA (1:1,000) or
anti-tubulin (clone DM1A, ascites fluid, 1:10,000, Sigma-Aldrich, St Louis, MO, USA) antibody
diluted in blocking buffer, overnight at 4°C. After washing, the membranes were incubated
with secondary antibody (anti-rabbit/mouse IgG IRDye 800CW [Westburg, Leusden, The
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Netherlands]) diluted 1:10,000 in blocking buffer, for 1 h at RT. Blots were scanned on an
Odyssey image scanner (GE Healthcare, Munich, Germany).
Histochemistry and Purkinje cell (PC) quantification
Tissue sections were stained with hematoxylin and eosin (HE). Parasagittal sections of cerebel-
lum were scanned using an Olympus BX61VS microscope with UPlanSApo 20x/0.75 objective
and TIFF images were acquired using the Olympus dotSlide system (Olympus, Tokyo, Japan).
All those PCs were counted in which a nucleus with a nucleolus was observed. The PC layer
was traced and length of the trace was measured using ImageProPlus 7.0 software (Media
Cybernetics, Rockville, MD, USA). The number of PCs per unit of PC layer was quantified for
the anterior, central, posterior, and flocculonodular transversal zones of the cerebellum [21].
Erasmus ladder
We tested motor coordination of untreated and iminosugar treated (5 mg/kg.bw/day of MZ-
21) Npc1+/+, Npc1+/- and Npc1-/- mice using the Erasmus Ladder. Details on the device and its
software have been published before [22–24]. Both the recording and stimulating parts of the
setup are controlled by software written in LabView (National Instruments, Austin, TX, USA)
operating at a fixed cycle of 2 ms. All data collected are stored in a relational database (MySQL,
Oracle, Redwood Shores, CA, USA) and subsequently processed and analyzed off-line using
custom-written software in LabView and Python (Python Software Foundation, Beaverton,
OR, USA) as well as SPSS (IBM Corporation, Armonk, NY, USA). For the current study we fol-
lowed a modified version of a previously developed protocol [24]. In principle, if health status
permitted, each mouse had to perform 1 daily session during 5 days at the age of 6 weeks and
one daily session during 2 days at the age of 9 and 10 weeks. The sessions for the 6 weeks-old
stage included in consecutive order 3 non-perturbed sessions so as to adjust to the apparatus, 1
fix-obstacle session during which rung number 19 remained always elevated by 18 mm (i.e. 12
mm above the walking path), and 1 paired session in which the unconditioned stimulus (i.e.
elevated rung) was provided at a random location on the right side 200 ms following the onset
of the conditioned stimulus (i.e. a tone), which in turn depended on the predicted trajectory of
the mouse (for details see [22]). The sessions for the 9 and 10 weeks-old stages included 1 non-
perturbed session followed by 1 fix-obstacle session. During all sessions mice had to walk back
and forth between the 2 shelter boxes, and during all sessions, which always included 45 trials,
we took step time as the main outcome parameter, which was defined as the time (in ms) that
elapses between the onsets of two consecutive touches on the rungs.
Cholesterol measurement
Total cholesterol levels in brain homogenates were determined after lipid extraction according
to Folch [25] using a colorimetric enzymatic kit (Biolabo, Maizy, France).
Ganglioside quantification
Ganglioside composition was determined as previously described [26]. Asialo-ganglioside
GM1 from bovine brain (Sigma, St Louis, MO, USA) was used as an internal standard.
(Glyco)sphingolipid quantification
Levels of ceramide and of the isomers glucosylceramide and galactosylceramide were deter-
mined in homogenates of total brain after lipid extraction by modified Bligh and Dyer method
[27]. Neutral glycosphingolipids were separated from neutral lipids (ceramides and
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phospholipids) by Solid Phase Extraction (SPE) using a Backergrond Silica Gel (SiOH) SPE
column (1 mL, 100 mg per column). After deacylation with sphingolipid ceramide N-deacylase
(SCDase, Takara Bio Inc., Japan), glucosylceramide-borne glucosylsphingosine was digested
with recombinant GBA (imiglucerase, Genzyme) yielding freed sphingosine. Sphingoid bases
and lyso-glycosphingolipids were derivatized with O-phthaldialdehyde and analyzed by HPLC
as described before [28].
Glucosylsphingosine quantification
Glucosylsphingosine analysis was performed according to a previously described protocol [29].
Statistical analysis
Values presented in figures concerning the Npc1-/- mice represent mean ± s.e.m.. Statistics
were performed using the nonparametric Kruskal-Wallis test followed by a post hocDunn’s
multiple comparison test using GraphPad Prism 5 (Graph Pad Software, Inc., San Diego,
USA):  P< 0.05;  P< 0.01;  P< 0.001.
Results
GBA and GBA2 in wild-type and Npc1-/- mouse brain
The enzymes GBA and GBA2 in brain of end-stage Npc1-/- mice were examined employing a
recently developed activity-based probe to visualize these two β-glucosidases [19]. The activity-
based probe (ABP 1), a fluorescent aziridine phellitol-type suicide inhibitor (Fig 1A), labels
with high specificity and sensitivity through covalent binding to the catalytic nucleophile resi-
due in active GBA (half maximal inhibitory concentration (IC50) = 1.15 nM) and GBA2 (IC50
= 0.15 nM) enzyme molecules [19]. The two fluorescently-labeled enzymes can each be quanti-
tatively visualized following separation by SDS-PAGE electrophoresis.
While relative content of active GBA as assessed by ABP 1 labelling was not markedly
reduced (Fig 1B), active GBA2 was nevertheless found to be increased in lysates of brain of
85-day-old Npc1-/- mice (Fig 1B, see S1 Fig for band intensity quantification). Accordingly,
measurement of the activity of the two β-glucosidases with the 4-methylumbelliferyl-β-D-glu-
copyranoside (4MU-β-D-Glc) fluorogenic substrate revealed a significant increase (P = 0.0006)
of the GBA2/GBA ratio in Npc1-/- mice brain lysates (Fig 1C, see S1 Fig for individual activi-
ties). Increased GBA2 in brain of Npc1-/- mice was also observed at the protein level by Western
blot analysis with anti-GBA2 antibody (Fig 1B and S1 Fig). The cerebellum is one of the brain
areas most affected by neuropathology in NPC patients and Npc1-/- mice. In dissected cerebella
of 75-day-old Npc1-/- mice changes in relative amount of active GBA and GBA2 as detected by
ABP 1 labelling were less clear than in total brain (Fig 1D and S1 Fig) and the ratio of GBA2/
GBA activity assayed with artificial substrate was slightly (but not significantly) increased (Fig
1E and S1 Fig) compared to those in control wild-type (wt) mice. A similar increase in the ratio
was observed for the other brain areas analyzed (S2 Fig).
Next, we performed intracerebroventricular (ICV) infusion of ABP 1 into living rats. ABP 1
localized mainly to calbindin D-28K positive Purkinje cells (PCs) in the cerebellum (Fig 1F).
GBA labeling was blocked by pre-infusion with conduritol-β-epoxide. These findings strongly
suggest that PCs express active GBA2 in vivo (Herrera Moro et al. to be published in detail).
Using immunostaining on mouse cerebellum we found that GBA2 is particularly abundant in
these sole output neurons of the cerebellar cortex that are critical for motor coordination (Fig
1G) [30]. Double immunostaining revealed GBA2 to be present in the PC cell body as well as
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Fig 1. GBA and GBA2 in brain ofNpc1+/+ andNpc1-/- mice. (A) Chemical structures of ceramide (Cer), glucosylceramide (GlcCer), the ABP 1 specific for
GBA and GBA2, and the inhibitors AMP-DNM (MZ-21) and l-ido-AMP-DNM (MZ-31) with respective IC50 values. (B) Fluorescent labelling of GBA and GBA2
with ABP 1 andWestern blotting with anti-GBA2, anti-GBA and anti-tubulin antibodies in brain homogenates of 85-day-old Npc1+/+, Npc1+/- andNpc1-/-
mice. (C) Ratio of GBA2 and GBA enzymatic activities (assayed with 4MU-β-D-Glc substrate) in brain homogenates of 85-day-old Npc1+/+, Npc1+/- and
Npc1-/- mice. (D) Fluorescent labelling of GBA and GBA2 with ABP 1 andWestern blotting with anti-GBA2, anti-GBA and anti-tubulin antibodies in
Reducing GBA2 Ameliorates NPC Neuropathology
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the dendrites, whereas GBA is largely restricted to the PC cell body in a punctate distribution
pattern in agreement with lysosomal localization (Fig 1G).
We then studied the natural history of neuropathology in Npc1-/- mice with special attention
to GBA and GBA2. As reported earlier by others [31], progressive loss of PCs started in the
anterior cerebellum, as reflected by decreased staining for calbindin D-28K. Concomitantly,
astrogliosis (α-GFAP) increased in aging Npc1-/- mice. Surviving Npc1-/- PCs in the central and
more posterior cerebellum continued to express GBA and GBA2 (S3 Fig). Enlarged vesicular
structures in Npc1-/- PCs at day 80 did not stain for either GBA or GBA2, whereas the remain-
der of the PC cell body as well as the disorganized dendrites often co-stained for both GBA and
GBA2 (Fig 1G). Both GBA and GBA2 accumulated in axonal swellings that were observed at
days 60 and 80 in Npc1-/- cerebella (S3 Fig).
Impact of genetic deficiency of Gba2 on Npc1-/- mice
Since GBA2 activity was found to be relatively increased in Npc1-/- mice (Fig 1B and 1C), we
tested the consequence of introducing a genetic Gba2 loss in these animals. For this we crossed
Gba2-deficient mice (C57BL/6-129S6/SvEv) without an overt phenotype [17] with Npc1-/-
mice (BALB/c) to generate combined Npc1-/-/Gba2-/-. The genetic background of Npc1-/- mice
is reported to influence disease severity, being least severe in BALB/c animals [32]. This finding
was recapitulated: the average lifespan of Npc1-/- mice with mixed background being 73 days
(Fig 2A and 2B) compared to 83 days for animals with BALB/c background (see also Fig 3A
and 3B). In brains of Npc1-/-/Gba2+/+ mice with mixed background total GBA2 activity and
protein were elevated at end-stage (Fig 2C and 2D, S4 Fig), similar to that seen for animals
with the BALB/c background (Fig 1B and 1C).
Body weight, physical activity and motor coordination of mice with various combinations
of deficiencies in Npc1 and Gba2 were monitored. Mice were euthanized when weight loss
exceeded 30% of peak weight and the animals presented hunched posture, reduced activity and
were no longer able to remain upright due to trembling/shaking. As shown in the Kaplan-
Meier survival curves (Fig 2A), combined loss of Gba2 prolonged lifespan significantly in
Npc1-/- mice (P logrank = 0.0180 from Npc1-/-/Gba2+/+) and increased maximal bodyweight
(Fig 2B) compared to animals wild-type or heterozygous for this enzyme. Neurological symp-
toms—defective coordination and shaking (ataxia)–were delayed by 15 days in double-knock-
out mice (Fig 2B). Of note, Gba2 deficiency did significantly delay, but not fully prevent
complications. PC number appeared higher in the transversal cerebellar zones of 83-day-old
Npc1-/-/Gba2-/- mice compared to 73-day-old Npc1-/-/Gba2+/+ animals (Fig 2E and 2F), never-
theless this difference did not reach statistical significance (P = 0.1897, Fig 2F). Cerebellar cal-
bindin D-28K expression was more widespread and neurofilament containing axonal swelling
was less abundant in double-knockout mice compared to Npc1-/-/Gba2+/+ controls (Fig 2E). In
contrast, astrogliosis was not diminished by the genetic deficiency of Gba2, as evidenced by
abundant GFAP staining (Fig 2E).
homogenates of dissected cerebella of 75-day-oldNpc1+/+, Npc1+/- andNpc1-/-mice. (E) Ratio of GBA2 and GBA enzymatic activities (assayed with 4MU-
β-D-Glc substrate) in cerebellar homogenates of 75-day-oldNpc1+/+, Npc1+/- andNpc1-/- mice. (F) Fluorescent labelling of GBA2 with ABP 1 (top-right) in
wild-type rat cerebellum by ICV injection. GBA was pre-blocked with conduritol-β-epoxide. Sections were also labelled with DAPI (top-left) and
immunostained with anti-calbindin D-28K antibody (bottom-left). The arrow indicates a double-labelled cell. Scale bar = 50 μm. (G) Single immunostaining
with anti-calbindin D-28K and anti-GBA2 antibodies (top) and double immunostaining with anti-GBA and anti-GBA2 antibodies (bottom) of cerebellar sagittal
sections of 85-day-old Npc1+/+ andNpc1-/- mice. The arrows indicate PC cell body (white) and dendrites (grey). Scale bars = 100 μm (top) and 50 μm
(bottom).
doi:10.1371/journal.pone.0135889.g001
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Fig 2. Crossing ofGba2-/- (C57BL/6-129S6/SvEv) mice withNpc1-/- (BALB/c) mice. (A) Survival Kaplan-Meier plot of transgenic mice resulting from the
crossing of GBA2 deficiency into the Npc1-/- background (P logrank = 0.0180 from Npc1-/-/Gba2+/+). (B) Maximal bodyweight, average lifespan, percentage
lifespan increase and age at which bodyweight loss and neurological symptoms are patent in crossed animals. (C) Fluorescent labelling of GBA and GBA2
with ABP 1 (100 nM) andWestern blotting with anti-GBA2 and anti-tubulin antibodies in brain homogenates of end-stage transgenic male mice. (D) GBA2
activity (assayed with 4MU-β-D-Glc substrate) in brain homogenates of end-stage transgenic mice relative to Npc1+/+/Gba2+/+ (wt) values. (E) Sagittal
cerebellar sections of end-stage transgenic mice immunostainned with anti-calbindin D-28K, -neurofilament and -GFAP antibodies. The arrows indicate
calbindin D-28K positive cells (2nd panel from top) and swollen axons positive for neurofilament (3rd panel). Scale bar = 500 μm (top-panel) and 200 μm (other
panels). (F) PC count in the anterior (A), central (C), posterior (P) and flocculonodular (N) transversal zones of the cerebellum of end-stage transgenic mice.
Data (n = 5–6 per group, mean ± s.e.m.) were analyzed using the Kruskal-Wallis test with post hoc Dunn’s multiple comparison test.
doi:10.1371/journal.pone.0135889.g002
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Fig 3. Pharmacological inhibition of GBA2 in Npc1-/- (BALB/c) mice. (A) Kaplan-Meier survival plots of Npc1-/- mice treated with 1 and 5 mg/kg.bw/day
(mpk) of MZ-21 and MZ-31 (P logrank < 0.0001 from untreatedNpc1-/- mice). (B) Maximal bodyweight, average lifespan, percentage lifespan increase and
age at which bodyweight loss and neurological symptoms are patent in Npc1+/+ andNpc1-/- treated and untreated mice. (C) Fluorescent labelling of GBA and
GBA2 with ABP 1 and immunostaining with anti-GBA2 and -tubulin antibodies in brain homogenates of Npc1+/+, Npc1+/- andNpc1-/- treated and untreated
85- and 110-day-old mice. (D) GBA2 activity (assayed with 4MU-β-D-Glc substrate) in brain homogenates ofNpc1+/+, Npc1+/- andNpc1-/- treated and
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Impact of pharmacological inhibition of GBA2 on Npc1-/- mice
Having established that genetic loss of Gba2 ameliorates neuropathology in Npc1-/- mice, we
investigated whether such beneficial effect can also be obtained by pharmacological inhibition
of GBA2 activity. We have previously designed very potent inhibitors of GBA2, the hydropho-
bic aza-sugars AMP-DNM (MZ-21) and ido-AMP-DNM (MZ-31) (Fig 1A) [33]. Both aza-
sugars enter the brain well and inhibit GBA2 at low nanomolar concentration [34].
Npc1-/- mice (BALB/c background) were fed a diet calculated to deliver 1 or 5 mg/kg.bw/day
of MZ-21 or MZ-31. Again, iminosugar-mediated reduction of GBA2 activity increased lifespan
by 20–30 days (Fig 3A and 3B) and significantly delayed onset of weight loss and clinical mani-
festations of neurodegeneration (Fig 3B). We found that in iminosugar-treated animals GBA2
enzyme activity (Fig 3C and 3D), but not GBA2 protein (Fig 3C and S5 Fig), was completely
abrogated with either iminosugar at both doses. Additionally, the number of PCs in the cerebel-
lum of 85-day-old iminosugar-treated Npc1-/-mice was significantly higher (P< 0.05, Fig 3F)
than in age-matched untreated animals as assessed by PC counts in HE stainings (Fig 3F) and
calbindin D-28K immunostaining (Fig 3E). Further consistent with improved clinical status,
axonal swelling inNpc1-/-mice as indicated by neurofilament immunostaining was less exten-
sive following iminosugar treatment (Fig 3E). Extent of GFAP-positive astrogliosis however was
not affected (Fig 3E). Also staining for activated microglia and macrophages, using Iba-1 and
F4/80, were largely similar in Npc1-/-mice with and without iminosugar treatment (S6 Fig).
To evaluate the effect of pharmacological inhibition of GBA2 on motor coordination we
tested iminosugar-treated and untreated Npc1+/+, Npc1+/- and Npc1-/- mice on the Erasmus
Ladder [24]. Untreated Npc1-/- mice needed significantly longer time to make a single step than
Npc1+/+ controls at the ages of 6 (paired session, P = 0.0022) and 9 weeks (non-perturbed ses-
sion, P = 0.001; fix-obstacle session, P = 0.002) (Fig 3G). Remarkably, these differences were
not observed for the iminosugar-treated animals during the fix-obstacle session (P = 0.060)
(Fig 3G). Only at 10 weeks of age did iminosugar-treated Npc1-/- mice need significantly longer
time than controls to make a single step during the non-perturbed (P< 0.001) and the fix-
obstacle (P< 0.001) sessions (Fig 3G). Thus, as time progressed iminosugar-treated Npc1-/-
mice also developed impaired motor coordination, but the onset of the impairments was
delayed by about four weeks.
Brain lipids and lysosomes in iminosugar treated Npc1-/- mice
Given the primary role of cholesterol and ganglioside accumulation in lysosomes in NPC, we
next analyzed the impact of iminosugar treatment of Npc1-/- mice on brain lipid composition
and lysosomes. No significant differences between total brain cholesterol and ceramide levels
of age-matched (85-day-old) Npc1+/+, treated or untreated Npc1-/- mice were detected
(Table 1). Although not statistically significant, ceramide levels showed the trend to be elevated
in total brain of Npc1-/- mice compared to Npc1+/+ controls and tended to normalize with most
iminosugar treatment conditions (Table 1). In contrast, GlcCer and the gangliosides GM3 and
GM2 were increased in the brain of Npc1-/- untreated mice and these levels were not normal-
ized by MZ-21 or MZ-31 treatment (Table 1). Rather, GlcCer was more than 10-fold increased
untreated 85-day-old mice relative toNpc1+/+ (wt) values. (E) Sagittal cerebellar sections of 85-days-oldNpc1+/+ andNpc1-/- treated and untreated
immunostainned with antibodies against calbindin D-28K, neurofilament and GFAP. The arrows indicate calbindin D-28K positive cells (2nd panel from top)
and swollen axons positive for neurofilament (3rd panel). Scale bar = 500 μm (top-panel) and 200 μm (other panels). (F) PC count in the anterior, central,
posterior and flocculonodular areas of the cerebellum of Npc1-/- treated and untreated 85-day-old mice. The line indicatesNpc1+/+ levels. (G) Motor
coordination of untreated and treated Npc1-/- mice measured in the Erasmus Ladder. Step time (in ms) during perturbed sessions of Npc1+/+, Npc1+/- and
Npc1-/- untreated (top) and treated (bottom) mice at six (session 5), nine (sessions 6 & 7) and ten (sessions 8 & 9) weeks of age. Data (n = 4–12 per group,
mean ± s.e.m.) were analyzed using the Kruskal-Wallis test with post hoc Dunn’s multiple comparison test: * P < 0.05; ** P < 0.01; *** P < 0.001.
doi:10.1371/journal.pone.0135889.g003
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by iminosugar treatment (Table 1). The de-acylated form of GlcCer, glucosylsphingosine
(GlcSph), was also elevated in untreated animals and further increased by the treatment
(Table 1). Galactosylceramide (GalCer), the main component neuronal myelin sheaths, levels
were reduced by half in the brain of Npc1-/- mice, confirming that the profound CNS demyelin-
ation in these animals was not corrected by the treatment.
Table 1. Inhibition of GBA2 activity does not correct lysosomal defects.
Cholesterol
(μmol/g ww)
Glycosphingolipids (nmol/g ww) Activity (% wt)
Genotype Age
(d)
Treatment GalCer
(% wt)
GlcCer (%
wt)
Cer (%
wt)
GlcSph GM3 GM2 β-hexo β-
glucuro
Npc1+/+ 85 29.8 ± 0.3 100 ± 2 100 ± 1 100 ± 7 0.2 ± 0.0 12 ± 1 12 ± 4 100 ± 13 100 ± 14
Npc1+/- 85 33.2 ± 0.9 82 ± 7 74 ± 7 91 ± 7 0.2 ± 0.0 13 ± 2 10 ± 1 99 ± 5 77 ± 3
Npc1-/- 85 28.8 ± 0.7 45 ± 3* 311 ± 17 119 ± 10 1.4 ± 0.1 338 ± 12** 522 ± 15* 421 ± 17 291 ± 15*
85 1 (21) 26.1 ± 1.3 42 ± 3 1195 ± 142 75 ± 6 2.2 ± 0.5 229 ± 25 378 ± 12 430 ± 85 204 ± 30
85 5 (21) 29.5 ± 1.4 53 ± 6 1455 ± 171† 80 ± 5 2.3 ± 0.1 225 ± 24 396 ± 31 453 ± 92 275 ± 21
85 1 (31) 33.4 ± 0.2 53 ± 11 936 ± 86 82 ± 16 2.7 ± 0.0* 263 ± 25 448 ± 50 408 ± 15 239 ± 19
85 5 (31) 31.0 ± 1.0 60 ± 4 1599 ± 54†† 112 ± 3 2.2 ± 0.3 193 ± 4 310 ± 17 473 ± 54 256 ± 20
Npc1+/+ 110 N.A. 107 ± 8 115 ± 24 85 ± 8 0.3 ± 0.0 17 ± 3 11 ± 3 N.A. N.A.
Npc1-/- 110 1 (21) 24.2 ± 2.5 48 ± 2‡ 1181 ± 170 73 ± 11 3.1 ± 0.3 264 ± 2 412 ± 6 382 ± 17 255 ± 32
110 5 (21) 23.3 ± 3.8 58 ± 5 1381 ± 155 81 ± 2 3.7 ± 0.4 274 ± 28 477 ± 49 378 ± 78 193 ± 10
110 1 (31) 25.5 ± 2.7 48 ± 4 1015 ± 139 65 ± 4 3.1 ± 0.2 275 ± 2 442 ± 10 341 ± 53 256 ± 35
110 5 (31) 22.7 ± 1.7 65 ± 7 1572 ± 92‡ 97 ± 19 3.8 ± 0.6 293 ± 10 474 ± 9 450 ± 16 300 ± 15
Levels of GalCer, GlcCer, Cer, GlcSph and gangliosides (GM3 and GM2), and activity of lysosomal enzymes β-hexosaminidase and β-glucuronidase in
whole brain homogenates of Npc1+/+, Npc1+/- and Npc1-/- treated and untreated 85- and 110-day-old (BALB/c) mice. Data (n = 6–12 per group) were
analyzed using the Kruskal-Wallis test with post hoc Dunn’s multiple comparison test.
* P < 0.05 and
** P < 0.01 from untreated Npc1+/+ (85-day-old)
† P < 0.05 and
†† P < 0.01 from untreated Npc1+/- (85-day-old)
‡ P < 0.05 from untreated Npc1+/+ (110-day-old)
doi:10.1371/journal.pone.0135889.t001
Table 2. Genetic ablation ofGba2 does not correct lysosomal defects.
Cholesterol (μmol/g
ww)
Glycosphingolipids (nmol/g ww) Activity (%
wt)
GalCer (%
wt)
GlcCer (%
wt)
Cer (%
wt)
GlcSph GM3 GM2 β-hexo
Npc1-/-/Gba2-/- 13.8 ± 0.7 45 ± 3** 1096 ± 25*** 89 ± 9 4.5 ± 0.5*** 327 ± 16 335 ± 20* 333 ± 13
Npc1-/-/Gba2+/- 14.7 ± 0.7 53 ± 3 312 ± 10* 115 ± 7 2.6 ± 0.3* 402 ± 42** 384 ± 37** 352 ± 18
Npc1-/-/Gba2+/+ 14.1 ± 0.5 46 ± 4** 257 ± 22 102 ± 8 2.0 ± 0.3 299 ± 27 310 ± 23 364 ± 9
Npc1+/+/Gba2+/
+
16.2 ± 0.4 100 ± 6 100 ± 8 100 ± 5 0.3 ± 0.0 3 ± 2 1 ± 0 100 ± 5
Levels of GalCer, GlcCer, Cer, GlcSph and gangliosides (GM3 and GM2), and activity of lysosomal enzymes β-hexosaminidase in whole brain
homogenates of mice resulting from the crossing of Gba2-/- mice with Npc1-/- mice. Data (n = 5–6 per group) were analyzed using the Kruskal-Wallis test
with post hoc Dunn’s multiple comparison test.
* P < 0.05,
** P < 0.01 and
*** P < 0.001 from Npc1+/+/Gba2+/+
doi:10.1371/journal.pone.0135889.t002
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Lipid analysis of dissected cerebella gave very similar results to total brain (S7 Fig). Cer-
amide (P< 0.05), GlcCer (P< 0.05) and GlcSph (P< 0.001) levels were increased in the cere-
bellum of 75-day-old untreated Npc1-/- mice compared to age-matched wt animals. In end-
stage (115-day-old) Npc1-/-mice, treatment did not affect ceramide levels and aggravated eleva-
tions in GlcCer and GlcSph. GalCer was reduced in cerebellum of Npc1-/- mice.
As previously reported [12], lysosome markers (β-hexosaminidase and β-glucuronidase)
were elevated in brain of Npc1-/- mice as a consequence of lysosomal hypertrophy. Iminosugar-
treatment did not normalize these markers (Table 1). Noteworthy, the levels of cholesterol,
GSLs, GlcSph, and lysosome markers were similar in 85-day-old brains of Npc1-/-/Gba2-/- mice
compared to those in brains of age-matched iminosugar-treated Npc1-/- animals (Table 2).
Hence, pharmacological or genetic abrogation of GBA2 enzymatic activity while ameliorating
neurological manifestation does not concomitantly correct the lysosomal hypertrophy or the
accumulation of GSLs in the central nervous system of Npc1-/- mice.
Discussion
In the present study we examined the potential role of the non-lysosomal glucosylceramidase
GBA2 in neurological manifestations inNpc1-/- mice. Firstly, we established that GBA2 activity is
indeed abnormally high in the brain ofNpc1-/- mice. This was indicated by analysis of brain using
ABP–labelling of GBA2, as well as by detection of GBA2 in brain lysates byWestern blot and the
measurement of enzymatic activity. The enzyme was also found to be particularly abundant in
PCs. Even though we did not observe a striking reduction in GBA activity in theNpc1-/- CNS, as
assayed in vitro with ABP 1 and artificial substrate, the accumulation of GBA-substrates (GlcCer
and GlcSph) points to an impairment of the enzyme in vivo. Secondly, we examined the outcome
of introducing a genetic loss of GBA2 inNpc1-/- mice. This ablation led to a significant increase in
lifespan and amelioration of motor coordination, reflected by prolonged survival of PCs. Next, we
investigated whether the loss of the GBA2 protein as such or the absence of its activity exerted the
beneficial effect. Employing extremely potent GBA2 inhibitors (IC50 values< 5 nM), we observed
that administration of as little as 25 μg per mouse daily led to similar beneficial responses as
observed with genetic loss of GBA2, such as increased maximal body weight, delayed PC loss and
delayed onset of motor deficits. The genetic background of mice is known to influence severity of
disease manifestation inNpc1-/- animals [32]. Pharmacological inhibition of GBA2 in BALB/c
Npc1-/- mice led to a relatively larger increase in life span (27–38%, Fig 3B) than genetic loss of
GBA2 inNpc1-/- mice in mixed background (15% lifespan increase, Fig 2B). Whether this differ-
ence can be accounted to the different genetic backgrounds or points to an additional target for
the iminosugars next to GBA2 is presently unclear. It has to be stressed that low nanomolar con-
centrations of iminosugars were applied at which no other enzymes are known to be inhibited.
Our combined findings point out that GBA2 plays a role in the early neuropathology of
NPC disease in mice. Our study also reveals that pharmacological inhibition of GBA2 offers an
avenue to ameliorate neurological manifestation of NPC, in particular to delay the loss of
motor coordination.
Our study led to the unexpected finding that while genetic or pharmacological reduction of
GBA2 activity exerts beneficial effects in Npc1-/- mice this is not accompanied by reduction of
the ganglioside accumulation and lysosomal hypertrophy in the brains of these animals.
Clearly, reduction of GBA2 does not entirely prevent neuropathology, but rather delays this
process. It seems likely that for complete prevention of disease, the primary underlying defect
at the level of lysosomes should be resolved and further prevented. A combination therapy
with a low dose of cyclodextrins might offer good prospects in this regard [35]. Nevertheless, a
significant delay in loss of motor coordination in NPC patients through GBA2 activity, as
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observed in the mouse model, would be of great clinical value. In addition, our findings suggest
that extra-lysosomal processes during lysosomal deficiency contribute to disease manifestation,
a notion prior formulated by other researchers [8,36].
The molecular mechanism underlying the detrimental effect of cytosolic GBA2 activity on
NPC pathology is presently not known. It might be envisioned that over-production by GBA2
of cytosolic ceramide and/or sphingosine from GlcCer and GlcSph is harmful, for example
through induction of apoptosis or other cell death pathways in neuronal cells, particularly
those with high GBA2 activity such as PCs. Of note, excessive formation of ceramide by GBA2
has recently been reported to promote apoptosis in human melanoma cells [37]. Detection of
excessive cytosolic ceramide in NPC mice cerebella would require high-resolution in situmass-
spectrometry analysis, which at present is technically challenging. Our study renders no indica-
tion that the slightly elevated GlcSph in brains of Npc1-/- mice causes PC loss. The beneficial
pharmacological inhibition or genetic ablation of GBA2 both led to a small further increase in
GlcSph. At present it cannot be excluded that GBA2 has another unknown activity leading to
formation of toxic compounds, for example through trans-glycosylation of other lipid species.
A currently approved drug for NPC disease is N-butyl-1-deoxynojirimycin (Zavesca, Acte-
lion). N-alkylated iminosugars such as Zavesca inhibit GlcCer synthase (GCS), the enzyme cata-
lyzing the first step in the biosynthesis of GSLs [38]. Zavesca has been found to ameliorate GD
in mildly affected type 1 patients and was therefore approved for treatment of this condition
[39]. Since excessive gangliosides have been postulated to contribute to neuropathology in NPC
disease [40], the effect of Zavesca on NPC was studied in mouse models. At high concentrations
Zavesca was found to reduce inflammation and ganglioside accumulation in the CNS of NPC
mice, concomitantly delaying the onset of neuromotor symptoms [40]. In humans, treatment
with this iminosugar was reported to stabilize and in some cases improve neurological aspects
in NPC patients [41], leading to its registration as “orphan drug” for NPC disease in Europe. It
is relevant to point out in this context, that iminosugars like Zavesca are not specific GCS inhibi-
tors. They also inhibit the hydrolases involved in the degradation of GlcCer to ceramide: GBA
and GBA2 [4,6]. Zavesca inhibits GBA2 with much higher affinity than GCS (IC50 = 230 nM
versus IC50 = 50,000 nM, respectively) [42]. Inhibition of GBA2 activity may therefore partially
underlie the observed beneficial effect of Zavesca in NPC patients. The inhibitors used in our
study, AMP-DNM and L-ido-AMP-DNM, are far more specific GBA2 inhibitors than Zavesca.
Oral administration of AMP-DNMwas reported to increase survival of NPCmice and Sandhoff
disease mice [34,43]. The beneficial effects of AMP-DNM in the present study occurred at drug
concentrations at which effective inhibition of GCS is highly unlikely, whereas complete inhibi-
tion of GBA2 activity occurs. For further optimization of iminosugar-type drugs for NPC and
comparable disease conditions it will be key to establish firmly whether inhibition of GBA2 or
that of GCS, or even both enzymes, is required to exert an optimal clinical response.
In conclusion, GBA2 inhibition suffices to significantly increase lifespan of Npc1-/- mice
despite persistent lysosomal abnormalities. Evidently, reduction of this enzymatic activity in
Npc1-/- mice, or even genetic absence of the enzyme, does not completely prevent neurodegen-
eration. Nevertheless, our results suggest that pharmacological inhibition of GBA2 might result
in a clinically significant delay of neurological complications. Given their advantageous inhibi-
tory profile GBA2 inhibitors AMP-DNM (MZ-21) and l-ido-AMP-DNM (MZ-31) may serve
as lead components for drug development for NPC.
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S1 Fig. GBA and GBA2 activity in total brain and cerebellum of Npc1+/+, Npc1+/- and
Npc1-/- mice. Quantification of scanned band intensity of ABP 1-fluorescently labelled (slab
gel) and immuno-probed (Western blot) GBA and GBA2 in brain (A) and cerebellum (C)
homogenates of Npc1+/+, Npc1+/- and Npc1-/- mice (see Fig 1B and 1D). Intensity (arbitrary
units) was normalized to α-tubulin and expressed relative to wt (Npc1+/+) control. GBA and
GBA2 enzymatic activities (assayed with 4MU-β-D-Glc substrate) in brain (B) and cerebellum
(D) homogenates of Npc1+/+, Npc1+/- and Npc1-/- mice (see Fig 1C and 1E).
(TIF)
S2 Fig. GBA2/GBA activity ratio in brain areas of Npc1+/+, Npc1+/- and Npc1-/- mice. Ratio
of GBA2 and GBA enzymatic activities (assayed with 4MU-β-D-Glc substrate) in homogenates
of dissected pons-medulla, cortex, hippocampus, olfactory bulb, hypothalamus and remaining
brain (rest) of 75-day-old Npc1+/+, Npc1+/- and Npc1-/- mice.
(TIF)
S3 Fig. Natural history of GBA and GBA2 protein expression in the cerebellum. Sagittal cer-
ebellar sections of 40-, 60- and 80-day-old Npc1+/+ and Npc1-/- mice were single immunos-
tained with anti-calbindin D-28K and anti-GFAP antibodies. Staining patterns in the anterior
cerebellum indicate progressive loss of calbindin D-28K positive Purkinje cells and concomi-
tant increase of GFAP positive astrogliosis in Npc1-/- mice (top panels; scale bar = 500 μm).
Sagittal cerebellar sections of 40-, 60- and 80-day-old Npc1+/+ and Npc1-/- mice were double
immunostained with anti-GBA and anti-GBA2 antibodies. For the central cerebellar zones, in
the region where only few calbindin D-28K positive Purkinje cells remain in Npc1-/- mice at
day 80, staining patterns of anti-GBA and anti-GBA2 are each displayed separately (small bot-
tom panels; scale bar = 100 μm) and as composite image (large bottom panels; scale
bar = 100 μm). The arrows indicate Purkinje cells.
(TIF)
S4 Fig. Quantification of ABP 1-labelling and immunoprobing in brain homogenates of
end-stage Npc1-/- and Gba2-/- crossed animals. Quantification of scanned band intensity of
ABP1-fluorescently labelled (slab gel) GBA and GBA2 and immuno-probed (Western blot)
GBA2 in brain homogenates of end-stage Npc1-/- and Gba2-/- crossed animals (see Fig 2C).
Intensity (arbitrary units) was normalized to α-tubulin and expressed relative to wt (Npc1+/
+/Gba2+/+) control.
(TIF)
S5 Fig. Quantification of ABP 1-labelling and immunoprobing in brain homogenates of
Npc1+/+, Npc1+/- and Npc1-/- iminosugar-treated mice.Quantification of scanned band inten-
sity of ABP1-fluorescently labelled (slab gel) GBA and GBA2 and immuno-probed (Western
blot) GBA2 in brain homogenates of Npc1+/+, Npc1+/- and Npc1-/- iminosugar-treated and
untreated 85- and 110-day-old mice (see Fig 3C). Intensity (arbitrary units) was normalized to
α-tubulin and expressed relative to wt (Npc1+/+) control.
(TIF)
S6 Fig. Microglia and activated macrophage markers in Npc1-/- untreated and iminosugar-
treated mice. (A) Sagittal cerebellar sections of 85-day-old Npc1+/+ and Npc1-/- untreated mice
and treated with 1 mpk MZ21 stained with HE and immunostained with anti-Iba-1 and -F4/80
antibodies. Scale bar = 100 μm. (B) Klüver-PAS staining of sagittal cerebellar sections of
85-days old Npc1+/+ and Npc1-/- untreated mice and treated with 1 mpk MZ21. Scale
bar = 50 μm.
(TIF)
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S7 Fig. GSL levels in cerebella of iminosugar treated mice. Levels of ceramide, GlcCer, Gal-
Cer and GlcSph in dissected cerebella of Npc1+/+, Npc1+/- and Npc1-/- mice untreated (75 days
of age) and treated with 5 mpk MZ-21 (115 days of age).
(TIF)
S8 Fig. Validation of immunostainings. (A) Single indirect immunostaining using rabbit-
anti-GBA2 primary antibody, HRP-conjugated Goat-anti-Rabbit secondary antibody, and
DAB as substrate did detect Purkinje cells (PCs) in cerebellum of Npc1+/+/Gba2+/+ mice and
did not label PCs nor any other structures in cerebellum of Npc1-/-/Gba2-/- mice. Haematoxylin
was used as counterstain. (B) Cerebellum of Npc1+/-/Gba2-/- mice, which do not suffer from
NPC disease and maintain presence of PCs as shown in haematoxylin and eosin (HE) stained
sections, is not stained by anti-GBA2. (C) Double immunostaining directed against either first
GBA and then GBA2 or first GBA2 and then GBA on Npc1+/+/Gba2+/+ cerebellum showed
detection of GBA2 in PCs, both in the cell body and in the dendrites, and of GBA mainly in a
punctuated pattern in the PC cell body. Background staining with secondary AP- and HRP-
conjugated antibodies or with substrates VectorBlue and AMEC-Red was negligible. Methyl
Green was applied as counterstain. (D) Double immunostaining with anti-GBA and anti-
GBA2 revealed only binding of anti-GBA on PCs of Npc1-/-/Gba2-/- mice.
(TIF)
S1 Table. Age of euthanasia of individual Npc1-/- and Gba2-/- crossed animals.
(XLS)
S2 Table. Detailed statistical analysis of Kaplan-Meier survival plot of Npc1-/- and Gba2-/-
crossed animals.
(XLS)
S1 Text.
(DOC)
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